Detalles de la búsqueda
1.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Blood
; 143(17): 1713-1725, 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38194692
2.
Primary central nervous system marginal zone lymphoma.
Br J Haematol
; 204(1): 31-44, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38054330
3.
New hopes in relapsed refractory primary central nervous system lymphoma.
Curr Opin Oncol
; 35(5): 364-372, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37551946
4.
Prevention and management of secondary central nervous system lymphoma.
Haematologica
; 108(3): 673-689, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36384246
5.
Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis.
Hematol Oncol
; 41(1): 88-96, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36192141
6.
Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
CA Cancer J Clin
; 66(2): 153-71, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26773441
7.
CNS prophylaxis for diffuse large B-cell lymphoma.
Lancet Oncol
; 23(9): e416-e426, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36055310
8.
Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
Br J Haematol
; 199(4): 507-519, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35945164
9.
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project.
Hematol Oncol
; 40(5): 953-961, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36083035
10.
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.
Hematol Oncol
; 40(5): 846-856, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35854643
11.
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
Br J Haematol
; 192(1): 119-128, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33085777
12.
MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Br J Haematol
; 193(3): 497-505, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33620087
13.
Predicting outcomes in CNS lymphoma with ctDNA.
Blood
; 143(6): 478-480, 2024 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38329774
14.
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.
Blood
; 134(3): 252-262, 2019 07 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31118164
15.
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Blood
; 134(4): 353-362, 2019 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31101627
16.
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
Br J Haematol
; 189(5): 879-887, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31997308
17.
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
Blood
; 132(2): 179-186, 2018 07 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29720487
18.
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Haematologica
; 105(6): 1604-1612, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31537689
19.
Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.
Hematol Oncol
; 38(4): 501-508, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32602970
20.
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
Hematol Oncol
; 38(3): 257-265, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32356913